CN103130820B - 一种头孢呋辛赖氨酸的合成方法 - Google Patents
一种头孢呋辛赖氨酸的合成方法 Download PDFInfo
- Publication number
- CN103130820B CN103130820B CN201310105586.3A CN201310105586A CN103130820B CN 103130820 B CN103130820 B CN 103130820B CN 201310105586 A CN201310105586 A CN 201310105586A CN 103130820 B CN103130820 B CN 103130820B
- Authority
- CN
- China
- Prior art keywords
- solution
- cefuroxime
- acid
- add
- prepared
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- CWTDDXMYNOJAMX-QWFHXNHVSA-N (6r,7r)-3-(carbamoyloxymethyl)-7-[[(2z)-2-(furan-2-yl)-2-methoxyiminoacetyl]amino]-8-oxo-5-thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylic acid;(2s)-2,6-diaminohexanoic acid Chemical compound NCCCC[C@H](N)C(O)=O.N([C@@H]1C(N2C(=C(COC(N)=O)CS[C@@H]21)C(O)=O)=O)C(=O)\C(=N/OC)C1=CC=CO1 CWTDDXMYNOJAMX-QWFHXNHVSA-N 0.000 title claims abstract description 69
- 238000010189 synthetic method Methods 0.000 title claims abstract description 15
- 229960001668 cefuroxime Drugs 0.000 claims abstract description 41
- 229960000534 cefuroxime sodium Drugs 0.000 claims abstract description 39
- JFPVXVDWJQMJEE-IZRZKJBUSA-N cefuroxime Chemical compound N([C@@H]1C(N2C(=C(COC(N)=O)CS[C@@H]21)C(O)=O)=O)C(=O)\C(=N/OC)C1=CC=CO1 JFPVXVDWJQMJEE-IZRZKJBUSA-N 0.000 claims abstract description 30
- URDOHUPGIOGTKV-JTBFTWTJSA-M Cefuroxime sodium Chemical compound [Na+].N([C@@H]1C(N2C(=C(COC(N)=O)CS[C@@H]21)C([O-])=O)=O)C(=O)\C(=N/OC)C1=CC=CO1 URDOHUPGIOGTKV-JTBFTWTJSA-M 0.000 claims abstract description 25
- HSHGZXNAXBPPDL-HZGVNTEJSA-N 7beta-aminocephalosporanic acid Chemical compound S1CC(COC(=O)C)=C(C([O-])=O)N2C(=O)[C@@H]([NH3+])[C@@H]12 HSHGZXNAXBPPDL-HZGVNTEJSA-N 0.000 claims abstract description 24
- 239000013078 crystal Substances 0.000 claims abstract description 12
- OUSLHGWWWMRAIG-FBCAJUAOSA-N (6r,7r)-7-[[(2z)-2-(furan-2-yl)-2-methoxyiminoacetyl]amino]-3-(hydroxymethyl)-8-oxo-5-thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylic acid Chemical compound N([C@@H]1C(N2C(=C(CO)CS[C@@H]21)C(O)=O)=O)C(=O)\C(=N/OC)C1=CC=CO1 OUSLHGWWWMRAIG-FBCAJUAOSA-N 0.000 claims abstract description 11
- 238000002425 crystallisation Methods 0.000 claims abstract description 11
- 230000008025 crystallization Effects 0.000 claims abstract description 11
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 claims abstract description 8
- 238000006482 condensation reaction Methods 0.000 claims abstract description 8
- 239000011734 sodium Substances 0.000 claims abstract description 8
- 229910052708 sodium Inorganic materials 0.000 claims abstract description 8
- OEOIWYCWCDBOPA-UHFFFAOYSA-N 6-methyl-heptanoic acid Chemical compound CC(C)CCCCC(O)=O OEOIWYCWCDBOPA-UHFFFAOYSA-N 0.000 claims abstract description 6
- BVHLGVCQOALMSV-JEDNCBNOSA-N L-lysine hydrochloride Chemical compound Cl.NCCCC[C@H](N)C(O)=O BVHLGVCQOALMSV-JEDNCBNOSA-N 0.000 claims abstract description 6
- 150000001263 acyl chlorides Chemical class 0.000 claims abstract description 6
- 229960005337 lysine hydrochloride Drugs 0.000 claims abstract description 6
- 239000000243 solution Substances 0.000 claims description 117
- 238000003756 stirring Methods 0.000 claims description 74
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 claims description 47
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 44
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 claims description 27
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 claims description 25
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 claims description 23
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 claims description 22
- 239000000843 powder Substances 0.000 claims description 18
- 238000000034 method Methods 0.000 claims description 16
- 238000005406 washing Methods 0.000 claims description 16
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 claims description 15
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 claims description 15
- 239000008346 aqueous phase Substances 0.000 claims description 14
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 claims description 11
- WYURNTSHIVDZCO-UHFFFAOYSA-N Tetrahydrofuran Chemical compound C1CCOC1 WYURNTSHIVDZCO-UHFFFAOYSA-N 0.000 claims description 11
- -1 formyl cefuroxime acid Chemical compound 0.000 claims description 11
- 229910052757 nitrogen Inorganic materials 0.000 claims description 11
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 claims description 10
- 239000012074 organic phase Substances 0.000 claims description 10
- 238000001291 vacuum drying Methods 0.000 claims description 10
- ZMANZCXQSJIPKH-UHFFFAOYSA-N Triethylamine Chemical compound CCN(CC)CC ZMANZCXQSJIPKH-UHFFFAOYSA-N 0.000 claims description 9
- 238000001914 filtration Methods 0.000 claims description 9
- WRJWRGBVPUUDLA-UHFFFAOYSA-N chlorosulfonyl isocyanate Chemical compound ClS(=O)(=O)N=C=O WRJWRGBVPUUDLA-UHFFFAOYSA-N 0.000 claims description 8
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 claims description 7
- 239000007864 aqueous solution Substances 0.000 claims description 6
- 239000012071 phase Substances 0.000 claims description 6
- 239000000725 suspension Substances 0.000 claims description 6
- 229960000583 acetic acid Drugs 0.000 claims description 5
- 239000012362 glacial acetic acid Substances 0.000 claims description 5
- YLQBMQCUIZJEEH-UHFFFAOYSA-N tetrahydrofuran Natural products C=1C=COC=1 YLQBMQCUIZJEEH-UHFFFAOYSA-N 0.000 claims description 5
- 239000002253 acid Substances 0.000 claims description 4
- 238000004821 distillation Methods 0.000 claims description 4
- 238000011049 filling Methods 0.000 claims description 4
- 238000011146 sterile filtration Methods 0.000 claims description 4
- 238000000967 suction filtration Methods 0.000 claims description 4
- 239000008215 water for injection Substances 0.000 claims description 4
- NGNBDVOYPDDBFK-UHFFFAOYSA-N 2-[2,4-di(pentan-2-yl)phenoxy]acetyl chloride Chemical compound CCCC(C)C1=CC=C(OCC(Cl)=O)C(C(C)CCC)=C1 NGNBDVOYPDDBFK-UHFFFAOYSA-N 0.000 claims description 3
- 238000004140 cleaning Methods 0.000 claims description 3
- 238000004128 high performance liquid chromatography Methods 0.000 claims description 3
- 239000008174 sterile solution Substances 0.000 claims description 3
- 239000012141 concentrate Substances 0.000 claims description 2
- 238000012544 monitoring process Methods 0.000 claims description 2
- 238000012360 testing method Methods 0.000 description 26
- 238000006243 chemical reaction Methods 0.000 description 21
- 239000012535 impurity Substances 0.000 description 15
- 238000002360 preparation method Methods 0.000 description 13
- 238000001819 mass spectrum Methods 0.000 description 9
- 239000007924 injection Substances 0.000 description 8
- 238000002347 injection Methods 0.000 description 8
- 238000004806 packaging method and process Methods 0.000 description 8
- 239000000047 product Substances 0.000 description 7
- 238000012552 review Methods 0.000 description 7
- 238000005070 sampling Methods 0.000 description 7
- 238000004088 simulation Methods 0.000 description 6
- 238000013112 stability test Methods 0.000 description 6
- 238000005481 NMR spectroscopy Methods 0.000 description 5
- 150000002500 ions Chemical class 0.000 description 5
- 238000002411 thermogravimetry Methods 0.000 description 5
- JFPVXVDWJQMJEE-QMTHXVAHSA-N Cefuroxime Chemical compound N([C@@H]1C(N2C(=C(COC(N)=O)CS[C@@H]21)C(O)=O)=O)C(=O)C(=NOC)C1=CC=CO1 JFPVXVDWJQMJEE-QMTHXVAHSA-N 0.000 description 4
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 4
- 238000004458 analytical method Methods 0.000 description 4
- 238000004455 differential thermal analysis Methods 0.000 description 4
- 238000000605 extraction Methods 0.000 description 4
- 230000007774 longterm Effects 0.000 description 4
- 238000007789 sealing Methods 0.000 description 4
- 229940046284 zinacef Drugs 0.000 description 4
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 3
- KDXKERNSBIXSRK-YFKPBYRVSA-N L-lysine Chemical compound NCCCC[C@H](N)C(O)=O KDXKERNSBIXSRK-YFKPBYRVSA-N 0.000 description 3
- 229910052799 carbon Inorganic materials 0.000 description 3
- 239000003795 chemical substances by application Substances 0.000 description 3
- 230000007062 hydrolysis Effects 0.000 description 3
- 238000006460 hydrolysis reaction Methods 0.000 description 3
- 238000005286 illumination Methods 0.000 description 3
- 239000007791 liquid phase Substances 0.000 description 3
- 238000013517 stratification Methods 0.000 description 3
- 239000000126 substance Substances 0.000 description 3
- 125000002941 2-furyl group Chemical group O1C([*])=C([H])C([H])=C1[H] 0.000 description 2
- 241000894006 Bacteria Species 0.000 description 2
- 229930186147 Cephalosporin Natural products 0.000 description 2
- UIIMBOGNXHQVGW-UHFFFAOYSA-M Sodium bicarbonate Chemical compound [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 description 2
- 238000002441 X-ray diffraction Methods 0.000 description 2
- 238000000862 absorption spectrum Methods 0.000 description 2
- XAGFODPZIPBFFR-UHFFFAOYSA-N aluminium Chemical compound [Al] XAGFODPZIPBFFR-UHFFFAOYSA-N 0.000 description 2
- 229910052782 aluminium Inorganic materials 0.000 description 2
- 230000000844 anti-bacterial effect Effects 0.000 description 2
- 230000015572 biosynthetic process Effects 0.000 description 2
- 239000006227 byproduct Substances 0.000 description 2
- 238000001460 carbon-13 nuclear magnetic resonance spectrum Methods 0.000 description 2
- 229940124587 cephalosporin Drugs 0.000 description 2
- 150000001780 cephalosporins Chemical class 0.000 description 2
- 150000001875 compounds Chemical class 0.000 description 2
- 238000009833 condensation Methods 0.000 description 2
- 230000005494 condensation Effects 0.000 description 2
- 238000001816 cooling Methods 0.000 description 2
- 239000012043 crude product Substances 0.000 description 2
- 238000000354 decomposition reaction Methods 0.000 description 2
- 239000003814 drug Substances 0.000 description 2
- 238000001035 drying Methods 0.000 description 2
- 238000005516 engineering process Methods 0.000 description 2
- 238000002474 experimental method Methods 0.000 description 2
- 239000000706 filtrate Substances 0.000 description 2
- 125000002485 formyl group Chemical group [H]C(*)=O 0.000 description 2
- 239000000543 intermediate Substances 0.000 description 2
- 239000006210 lotion Substances 0.000 description 2
- 238000000634 powder X-ray diffraction Methods 0.000 description 2
- 238000000425 proton nuclear magnetic resonance spectrum Methods 0.000 description 2
- 239000008213 purified water Substances 0.000 description 2
- 150000003839 salts Chemical class 0.000 description 2
- 239000002904 solvent Substances 0.000 description 2
- 238000001228 spectrum Methods 0.000 description 2
- 239000007921 spray Substances 0.000 description 2
- 238000003786 synthesis reaction Methods 0.000 description 2
- 238000010792 warming Methods 0.000 description 2
- JFPVXVDWJQMJEE-SWWZKJRFSA-N 55268-75-2 Chemical compound N([C@@H]1C(N2C(=C(COC(N)=O)CS[C@@H]21)C(O)=O)=O)C(=O)/C(=N/OC)C1=CC=CO1 JFPVXVDWJQMJEE-SWWZKJRFSA-N 0.000 description 1
- 239000005695 Ammonium acetate Substances 0.000 description 1
- 101710116957 D-alanyl-D-alanine carboxypeptidase Proteins 0.000 description 1
- 108090000204 Dipeptidase 1 Proteins 0.000 description 1
- 238000005033 Fourier transform infrared spectroscopy Methods 0.000 description 1
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 description 1
- KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 description 1
- 239000004472 Lysine Substances 0.000 description 1
- 230000006181 N-acylation Effects 0.000 description 1
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 1
- 102100025490 Slit homolog 1 protein Human genes 0.000 description 1
- 101710123186 Slit homolog 1 protein Proteins 0.000 description 1
- VMHLLURERBWHNL-UHFFFAOYSA-M Sodium acetate Chemical compound [Na+].CC([O-])=O VMHLLURERBWHNL-UHFFFAOYSA-M 0.000 description 1
- IWBUYGUPYWKAMK-UHFFFAOYSA-N [AlH3].[N] Chemical compound [AlH3].[N] IWBUYGUPYWKAMK-UHFFFAOYSA-N 0.000 description 1
- 238000004847 absorption spectroscopy Methods 0.000 description 1
- 230000001133 acceleration Effects 0.000 description 1
- ODFJOVXVLFUVNQ-UHFFFAOYSA-N acetarsol Chemical compound CC(=O)NC1=CC([As](O)(O)=O)=CC=C1O ODFJOVXVLFUVNQ-UHFFFAOYSA-N 0.000 description 1
- 239000008351 acetate buffer Substances 0.000 description 1
- WETWJCDKMRHUPV-UHFFFAOYSA-N acetyl chloride Chemical compound CC(Cl)=O WETWJCDKMRHUPV-UHFFFAOYSA-N 0.000 description 1
- 239000012346 acetyl chloride Substances 0.000 description 1
- 125000002777 acetyl group Chemical group [H]C([H])([H])C(*)=O 0.000 description 1
- 238000005917 acylation reaction Methods 0.000 description 1
- 239000003513 alkali Substances 0.000 description 1
- 229940043376 ammonium acetate Drugs 0.000 description 1
- 235000019257 ammonium acetate Nutrition 0.000 description 1
- 239000003242 anti bacterial agent Substances 0.000 description 1
- 229940088710 antibiotic agent Drugs 0.000 description 1
- 230000001580 bacterial effect Effects 0.000 description 1
- 102000006635 beta-lactamase Human genes 0.000 description 1
- 230000033228 biological regulation Effects 0.000 description 1
- 210000000988 bone and bone Anatomy 0.000 description 1
- 230000032823 cell division Effects 0.000 description 1
- 230000010261 cell growth Effects 0.000 description 1
- 210000000170 cell membrane Anatomy 0.000 description 1
- 239000007795 chemical reaction product Substances 0.000 description 1
- 238000005957 chlorosulfonylation reaction Methods 0.000 description 1
- 238000012790 confirmation Methods 0.000 description 1
- 230000001186 cumulative effect Effects 0.000 description 1
- 238000003381 deacetylation reaction Methods 0.000 description 1
- 238000006356 dehydrogenation reaction Methods 0.000 description 1
- 238000002050 diffraction method Methods 0.000 description 1
- 238000004090 dissolution Methods 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 230000000694 effects Effects 0.000 description 1
- 238000010828 elution Methods 0.000 description 1
- 239000012467 final product Substances 0.000 description 1
- 238000007710 freezing Methods 0.000 description 1
- 230000008014 freezing Effects 0.000 description 1
- 150000002240 furans Chemical class 0.000 description 1
- 229910052739 hydrogen Inorganic materials 0.000 description 1
- 239000001257 hydrogen Substances 0.000 description 1
- 208000015181 infectious disease Diseases 0.000 description 1
- 150000002596 lactones Chemical class 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 229960003646 lysine Drugs 0.000 description 1
- 238000012423 maintenance Methods 0.000 description 1
- 230000014759 maintenance of location Effects 0.000 description 1
- 238000004949 mass spectrometry Methods 0.000 description 1
- 230000010534 mechanism of action Effects 0.000 description 1
- 238000002156 mixing Methods 0.000 description 1
- 239000000203 mixture Substances 0.000 description 1
- 230000005311 nuclear magnetism Effects 0.000 description 1
- 238000005935 nucleophilic addition reaction Methods 0.000 description 1
- FPLYNRPOIZEADP-UHFFFAOYSA-N octylsilane Chemical group CCCCCCCC[SiH3] FPLYNRPOIZEADP-UHFFFAOYSA-N 0.000 description 1
- 230000009965 odorless effect Effects 0.000 description 1
- 238000005191 phase separation Methods 0.000 description 1
- 229920000642 polymer Polymers 0.000 description 1
- 238000001556 precipitation Methods 0.000 description 1
- 238000000746 purification Methods 0.000 description 1
- 238000012797 qualification Methods 0.000 description 1
- 239000002994 raw material Substances 0.000 description 1
- 239000000376 reactant Substances 0.000 description 1
- 238000007670 refining Methods 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 239000013557 residual solvent Substances 0.000 description 1
- 210000002345 respiratory system Anatomy 0.000 description 1
- 230000035945 sensitivity Effects 0.000 description 1
- 238000007086 side reaction Methods 0.000 description 1
- 239000000741 silica gel Substances 0.000 description 1
- 229910002027 silica gel Inorganic materials 0.000 description 1
- 210000003491 skin Anatomy 0.000 description 1
- 239000001632 sodium acetate Substances 0.000 description 1
- 229960004249 sodium acetate Drugs 0.000 description 1
- 235000017281 sodium acetate Nutrition 0.000 description 1
- 235000017557 sodium bicarbonate Nutrition 0.000 description 1
- 229910000030 sodium bicarbonate Inorganic materials 0.000 description 1
- 150000003388 sodium compounds Chemical class 0.000 description 1
- 210000004872 soft tissue Anatomy 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 238000010183 spectrum analysis Methods 0.000 description 1
- 230000001629 suppression Effects 0.000 description 1
- 238000012546 transfer Methods 0.000 description 1
- 230000001131 transforming effect Effects 0.000 description 1
- UCPYLLCMEDAXFR-UHFFFAOYSA-N triphosgene Chemical compound ClC(Cl)(Cl)OC(=O)OC(Cl)(Cl)Cl UCPYLLCMEDAXFR-UHFFFAOYSA-N 0.000 description 1
- 230000002485 urinary effect Effects 0.000 description 1
- 238000003828 vacuum filtration Methods 0.000 description 1
Landscapes
- Cephalosporin Compounds (AREA)
Abstract
Description
Claims (1)
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201310105586.3A CN103130820B (zh) | 2013-03-29 | 2013-03-29 | 一种头孢呋辛赖氨酸的合成方法 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201310105586.3A CN103130820B (zh) | 2013-03-29 | 2013-03-29 | 一种头孢呋辛赖氨酸的合成方法 |
Publications (2)
Publication Number | Publication Date |
---|---|
CN103130820A CN103130820A (zh) | 2013-06-05 |
CN103130820B true CN103130820B (zh) | 2015-08-05 |
Family
ID=48491320
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN201310105586.3A Active CN103130820B (zh) | 2013-03-29 | 2013-03-29 | 一种头孢呋辛赖氨酸的合成方法 |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN103130820B (zh) |
Families Citing this family (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN109988183B (zh) * | 2019-04-17 | 2020-12-08 | 广东立国制药有限公司 | 一种头孢呋辛酸的中间体的环保制备方法 |
CN113372363B (zh) * | 2021-04-15 | 2022-11-25 | 广东立国制药有限公司 | 一种去氨甲酰头孢呋辛的制备方法 |
Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4128715A (en) * | 1976-04-28 | 1978-12-05 | Glaxo Laboratories Limited | Cephalosporin antibiotics |
CN101830914A (zh) * | 2010-06-04 | 2010-09-15 | 杨铁耀 | 头孢呋辛赖氨酸结晶化合物及其制备方法 |
CN102134252A (zh) * | 2010-01-27 | 2011-07-27 | 四平市精细化学品有限公司 | 一种高纯头孢呋辛酸的制备方法 |
-
2013
- 2013-03-29 CN CN201310105586.3A patent/CN103130820B/zh active Active
Patent Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4128715A (en) * | 1976-04-28 | 1978-12-05 | Glaxo Laboratories Limited | Cephalosporin antibiotics |
CN102134252A (zh) * | 2010-01-27 | 2011-07-27 | 四平市精细化学品有限公司 | 一种高纯头孢呋辛酸的制备方法 |
CN101830914A (zh) * | 2010-06-04 | 2010-09-15 | 杨铁耀 | 头孢呋辛赖氨酸结晶化合物及其制备方法 |
Also Published As
Publication number | Publication date |
---|---|
CN103130820A (zh) | 2013-06-05 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CZ97599A3 (cs) | Cefemový derivát a způsob jeho výroby | |
CN102161667B (zh) | 磺苄西林钠及注射用磺苄西林钠 | |
CN110372727B (zh) | 头孢妥仑酸δ3异构体及头孢妥仑匹酯δ3异构体的制备方法 | |
CN103130820B (zh) | 一种头孢呋辛赖氨酸的合成方法 | |
CN103601739A (zh) | 一种头孢西丁钠化合物及其制备方法 | |
CN103159784B (zh) | 一种头孢呋辛赖氨酸及其制剂 | |
US8722863B2 (en) | Solid state forms of fidaxomycin and processes for preparation thereof | |
CN105440054B (zh) | 一种制备头孢硫脒的工艺 | |
CN102321100B (zh) | 头孢米诺钠的制备方法 | |
CN109134500A (zh) | 一种1/2水头孢拉定化合物 | |
CN109096304A (zh) | 一种3/4水头孢呋辛钠化合物 | |
CN102391326B (zh) | 一种盐酸克林霉素棕榈酸酯化合物及其制法 | |
CN103159785B (zh) | 一种头孢呋辛赖氨酸及其制剂 | |
WO2018067805A1 (en) | Solid state forms of sotagliflozin | |
CN108047237B (zh) | 一种四氢吡喃[2,3-b]吲哚骨架物及其晶体和其制备方法与用途 | |
CN103145734B (zh) | 一种头孢呋辛赖氨酸及其制剂 | |
CN106432278A (zh) | 一种治疗外科手术感染的药物头孢曲松钠晶体化合物 | |
CN106432274A (zh) | 一种治疗外科手术感染的药物头孢曲松钠晶体化合物 | |
CN103130821B (zh) | 一种头孢呋辛赖氨酸及其制剂 | |
CN102363621B (zh) | 头孢米诺钠六水合物及其制备方法和含有该水合物的药物组合物 | |
CN106432279A (zh) | 一种制备治疗外科手术感染的药物头孢曲松钠晶体化合物的方法 | |
CN107324998B (zh) | 一种制备外用抗生素类药物瑞他莫林的方法 | |
MXPA02000058A (es) | Sal difosfato de un derivado de 4" -sustituido-9-desoxo-9a-homoeritromicina y su composicion farmaceutica. | |
CN112521435B (zh) | 一种罗红霉素类似物在制备抗菌药物中的应用 | |
CN112480146B (zh) | 一种头孢呋辛酸混合溶剂化物、晶型及制备方法 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
C06 | Publication | ||
PB01 | Publication | ||
C10 | Entry into substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
ASS | Succession or assignment of patent right |
Owner name: SHANDONG LUOXIN PHARMACY GROUP CO., LTD. Free format text: FORMER OWNER: SHANDONG LUOXIN PHARMACY STOCK CO., LTD. Effective date: 20150630 Owner name: SHANDONG YUXIN PHARMACEUTICAL CO., LTD. SHANDONG H Effective date: 20150630 |
|
C41 | Transfer of patent application or patent right or utility model | ||
C53 | Correction of patent for invention or patent application | ||
CB03 | Change of inventor or designer information |
Inventor after: Ji Honghai Inventor after: Sun Yiwei Inventor after: Ruan Xizhe Inventor after: Li Mingjie Inventor after: Liu Mingxia Inventor after: Li Hua Inventor after: He Yaguan Inventor before: Li Mingjie Inventor before: Liu Mingxia Inventor before: Li Hua Inventor before: He Yaguan |
|
COR | Change of bibliographic data |
Free format text: CORRECT: INVENTOR; FROM: LI MINGJIE LIU MINGXIA LI HUA HE YAGUAN TO: JI HONGHAI SUN YIWEI RUAN XIZHE LI MINGJIE LIU MINGXIA LI HUA HE YAGUAN |
|
TA01 | Transfer of patent application right |
Effective date of registration: 20150630 Address after: Seven of 276017 Shandong province Linyi city Luozhuang District Applicant after: Shandong Luo Xin Pharmaceutical Group Plc Applicant after: Shandong Yu Xin pharmaceutcal corporation, Ltd Applicant after: SHANDONG HENGXIN PHARMACEUTICAL CO., LTD. Address before: Seven of 276017 Shandong province Linyi city Luozhuang District Applicant before: SHANDONG LUOXIN PHARMACY STOCK Co., LTD. |
|
C14 | Grant of patent or utility model | ||
GR01 | Patent grant | ||
CP03 | Change of name, title or address | ||
CP03 | Change of name, title or address |
Address after: 276017 18 Luo Qi Road, Luozhuang District, Linyi, Shandong Co-patentee after: Shandong Yu Xin pharmaceutcal corporation, Ltd Patentee after: Shandong Luo Xin Pharmaceutical Group Plc Co-patentee after: Shandong Luoxin Pharmaceutical Group Hengxin Pharmacy Co., Ltd. Address before: 276017 Luoqi Road, Luozhuang District, Linyi City, Shandong Province Co-patentee before: Shandong Yu Xin pharmaceutcal corporation, Ltd Patentee before: Shandong Luo Xin Pharmaceutical Group Plc Co-patentee before: SHANDONG HENGXIN PHARMACEUTICAL CO., LTD. |